Cell-Free DNA Sequencing Test for Infectious Disease Analyzed
By LabMedica International staff writers Posted on 22 Nov 2018 |
Image: The Karius test is a comprehensive next-generation sequencing (NGS) assay performed by the CLIA-certified and CAP-accredited Karius laboratory to identify and quantify microbial cell-free DNA in plasma from more than 1,000 bacteria, DNA viruses, fungi, molds, and protozoa (Photo courtesy of Karius).
A number of clinical collaborators testing a cell-free DNA sequencing test for infectious disease reported interim study results and anecdotal evidence of the assay.
Karius (Redwood City, CA, USA) has been developing technology to isolate cell-free pathogen DNA from blood. It is aiming its technology in particular at finding the cause of sepsis and for diagnosing infection in immunocompromised patients.
Investigator at St. Jude Children's Research Hospital (Memphis, TN, USA) enrolled patients who had refractory or relapsed acute Lymphatic Leukemia (ALL) or Acute myeloid leukemia (AML). For patients who developed bloodstream infections, standard culture-based diagnostics were carried out, but the Karius test was also run on any samples that were available up to seven days before a diagnosis was made up through seven days after the diagnosis. The goal was to determine whether the Karius test could identify the pathogen before a diagnosis was made by culture. The Karius test was able to identify the pathogen that was ultimately diagnosed by culture in nine out of 11 cases. In 10 of the cases, the scientists also had blood samples from the three days prior to culture diagnosis and the Karius test was able to identify the pathogen in eight of those samples.
The team also analyzed samples from 16 patients without infections and while the Karius test did identify bacteria and fungi in three of those cases, none of those organisms were associated with bloodstream infections. Kathryn Goggin, MD, a clinical investigator and senior study author, said, “That in a number of cases Karius identified other microbes aside from the causative pathogen, and said that those findings had "unclear clinical significance.” Those cases, she noted, could be polymicrobial infections, contamination, or even a phenomena known as gut bacterial translocation, where indigenous intestinal bacteria invade other tissues and organs and can lead to bloodstream infection. The condition is more common in immunocompromised individuals.
The study was presented at the Infectious Diseases Society of America's annual IDWeek conference held October 3-7, 2018, in San Francisco, CA, USA.
Related Links:
Karius
St. Jude Children's Research Hospital
Karius (Redwood City, CA, USA) has been developing technology to isolate cell-free pathogen DNA from blood. It is aiming its technology in particular at finding the cause of sepsis and for diagnosing infection in immunocompromised patients.
Investigator at St. Jude Children's Research Hospital (Memphis, TN, USA) enrolled patients who had refractory or relapsed acute Lymphatic Leukemia (ALL) or Acute myeloid leukemia (AML). For patients who developed bloodstream infections, standard culture-based diagnostics were carried out, but the Karius test was also run on any samples that were available up to seven days before a diagnosis was made up through seven days after the diagnosis. The goal was to determine whether the Karius test could identify the pathogen before a diagnosis was made by culture. The Karius test was able to identify the pathogen that was ultimately diagnosed by culture in nine out of 11 cases. In 10 of the cases, the scientists also had blood samples from the three days prior to culture diagnosis and the Karius test was able to identify the pathogen in eight of those samples.
The team also analyzed samples from 16 patients without infections and while the Karius test did identify bacteria and fungi in three of those cases, none of those organisms were associated with bloodstream infections. Kathryn Goggin, MD, a clinical investigator and senior study author, said, “That in a number of cases Karius identified other microbes aside from the causative pathogen, and said that those findings had "unclear clinical significance.” Those cases, she noted, could be polymicrobial infections, contamination, or even a phenomena known as gut bacterial translocation, where indigenous intestinal bacteria invade other tissues and organs and can lead to bloodstream infection. The condition is more common in immunocompromised individuals.
The study was presented at the Infectious Diseases Society of America's annual IDWeek conference held October 3-7, 2018, in San Francisco, CA, USA.
Related Links:
Karius
St. Jude Children's Research Hospital
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans